Material Insights · Understanding the Material World

CAR-T cell therapy: Evolution

Timeline

The milestones from first idea to today

YearMilestone
1989Gross, Waks and Eshhar publish the first chimeric antigen receptors [2]
2010CTL019, later Kymriah, is first tested at Penn in adults with chronic lymphocytic leukaemia [4]
2012The Children's Hospital of Philadelphia begins studying it in children with leukaemia; Penn and Novartis start a global collaboration [4]
2017The FDA approves Kymriah on 30 August, the first CAR-T therapy [3]; a second follows that year [8]
2025Seven CAR-T therapies are approved in the United States [1]

as of 2026-11-11

Lineage

The technologies it came from and the ones that came from it

Came before it
  • mAb Monoclonal antibodies Monoclonal antibodies made it possible to choose a marker to aim at; the 1989 receptors gave T cells antibody-type specificity [2].
Builds on

as of 2026-11-11

Sources

  1. CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers National Cancer Institute (NIH), 2025
  2. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proceedings of the National Academy of Sciences (Gross, Waks, Eshhar), record at MIGAL, 1989
  3. FDA Approves Novartis' CAR-T Drug, First Gene Therapy Approval in US Pharmaceutical Technology, 2017
  4. FDA Approves Personalized Cellular Therapy for Advanced Leukemia (news release) Penn Medicine, 2017
  5. Cells as cancer drugs National Cancer Institute, Center for Cancer Research